

PRODUCT MONOGRAPH  
INCLUDING PATIENT MEDICATION INFORMATION

**Pr BIVALIRUDIN INJECTION**

Bivalirudin injection

Sterile Solution

250 mg / 50 mL (5 mg/mL)

Ready-to-use, Intravenous Injection

Direct Thrombin Inhibitor

**AVIR Pharma Inc.**  
660 Boulevard Industriel,  
Blainville, Québec  
J7C 3V4

Date of Initial Approval:  
September 24, 2020

Submission Control No: 232423

## RECENT MAJOR LABEL CHANGES

Not applicable.

## TABLE OF CONTENTS

<b>TABLE OF CONTENTS</b> .....	<b>2</b>
<b>PART I: HEALTH PROFESSIONAL INFORMATION</b> .....	<b>4</b>
<b>1 INDICATIONS</b> .....	<b>4</b>
1.1 Pediatrics (< 18 years of age) .....	4
<b>2 CONTRAINDICATIONS</b> .....	<b>4</b>
<b>3 DOSAGE AND ADMINISTRATION</b> .....	<b>5</b>
3.1 Dosing Considerations .....	5
3.2 Recommended Dose and Dosage Adjustment.....	5
3.3 Administration .....	8
<b>4 OVERDOSAGE</b> .....	<b>9</b>
<b>5 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING</b> .....	<b>10</b>
<b>6 WARNINGS AND PRECAUTIONS</b> .....	<b>10</b>
6.1 Special Populations .....	11
6.1.1 Pregnant Women.....	11
6.1.2 Breast-feeding .....	12
6.1.3 Pediatrics .....	12
6.1.4 Geriatrics.....	12
<b>7 ADVERSE REACTIONS</b> .....	<b>12</b>
7.1 Adverse Reaction Overview .....	12
7.2 Clinical Trial Adverse Reactions.....	13
7.3 Less Common Clinical Trial Adverse Reactions .....	19
7.4 Post-Market Adverse Reactions.....	19
<b>8 DRUG INTERACTIONS</b> .....	<b>19</b>
8.1 Overview.....	19
<b>9 ACTION AND CLINICAL PHARMACOLOGY</b> .....	<b>20</b>
9.1 Mechanism of Action.....	20
9.2 Pharmacodynamics .....	20
9.3 Pharmacokinetics.....	21
<b>10 STORAGE, STABILITY AND DISPOSAL</b> .....	<b>23</b>
<b>PART II: SCIENTIFIC INFORMATION</b> .....	<b>24</b>
<b>11 PHARMACEUTICAL INFORMATION</b> .....	<b>24</b>
<b>12 CLINICAL TRIALS</b> .....	<b>25</b>
12.1 Trial Design and Study Demographics .....	25
12.2 Study Results.....	28
<b>13 NON-CLINICAL TOXICOLOGY</b> .....	<b>33</b>
<b>14 SUPPORTING PRODUCT MONOGRAPHS</b> .....	<b>35</b>



## PART I: HEALTH PROFESSIONAL INFORMATION

### 1 INDICATIONS

BIVALIRUDIN INJECTION (bivalirudin) is indicated for:

- use as an anticoagulant in patients undergoing percutaneous coronary intervention and in the treatment of patients with moderate to high risk acute coronary syndromes due to unstable angina or non-ST-segment elevation in whom early percutaneous coronary intervention is planned (see **DOSAGE AND ADMINISTRATION – Use Subsequent to Unfractionated Heparin (UFH) or Low Molecular Weight Heparin (LMWH)**)
- the treatment of patients with acute coronary syndromes due to ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI).

BIVALIRUDIN INJECTION is intended for use with acetylsalicylic acid (ASA) and has been studied only in patients receiving concomitant ASA. Clopidogrel can also be administered.

BIVALIRUDIN INJECTION is also indicated in patients with or at risk of heparin induced thrombocytopenia or heparin induced thrombocytopenia thrombosis syndrome (HIT/TS) undergoing PCI or cardiac surgery. BIVALIRUDIN INJECTION may be administered with or without ASA in patients undergoing cardiac surgery.

The safety and effectiveness of BIVALIRUDIN INJECTION have not been established in patients with acute coronary syndromes who are not undergoing PCI.

#### 1.1 Pediatrics (< 18 years of age)

No studies in patients under 18 years of age have been conducted with BIVALIRUDIN INJECTION.

### 2 CONTRAINDICATIONS

BIVALIRUDIN INJECTION (bivalirudin) is contraindicated in patients with:

- Hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see **DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING**
- Uncontrollable active bleeding
- Major blood clotting disorders
- Acute gastric or duodenal ulcer
- Cerebral hemorrhage
- Severe cerebro-spinal trauma
- Bacterial endocarditis
- Severe uncontrolled hypertension
- Diabetic or hemorrhagic retinopathy
- Proximal use of spinal/epidural anesthesia

### 3 DOSAGE AND ADMINISTRATION

#### 3.1 Dosing Considerations

- BIVALIRUDIN INJECTION (bivalirudin) should be administered with ASA. Clopidogrel can also be administered.
- Patients can be started with BIVALIRUDIN INJECTION 30 minutes after discontinuation of UFH given intravenously, or 8 hours after discontinuation of LMWH given subcutaneously.

#### 3.2 Recommended Dose and Dosage Adjustment

##### **UA/NSTEMI**

In patients presenting with unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI), the recommended dose of BIVALIRUDIN INJECTION is an initial intravenous bolus of 0.1 mg/kg bivalirudin followed by an infusion of 0.25 mg/kg/h prior to angiography and continued through angiography and as long as needed. The dose should be administered before assignment to a procedure (PCI, CABG, or drug therapy management).

Patients who are to be medically managed may continue the infusion of 0.25 mg/kg/h for up to 72 hours. No dosage adjustment is needed for these patients.

If the patient proceeds to PCI, an additional bolus of 0.5 mg/kg should be administered and the infusion increased to 1.75 mg/kg/h for the duration of the procedure. Following PCI, the reduced infusion dose of 0.25 mg/kg/h may be resumed for 4 to 12 hours as clinically necessary.

For patients who proceed to CABG surgery off-pump, the IV infusion of BIVALIRUDIN INJECTION should be continued until the time of surgery. Just prior to surgery, a 0.5 mg/kg bolus dose should be administered followed by a 1.75 mg/kg/h infusion for the duration of the surgery.

For patients who proceed to CABG surgery on-pump, the IV infusion of BIVALIRUDIN INJECTION should be continued until 1 hour prior to surgery after which the infusion should be discontinued and the patient treated with unfractionated heparin.

##### **PCI, Including Primary PCI**

The recommended dosage of BIVALIRUDIN INJECTION is an IV bolus of 0.75 mg/kg. This should be followed by an infusion of 1.75 mg/kg/h for the duration of the PCI procedure (see **Table 1**). Five (5) minutes after the bolus dose has been administered, an ACT (Activated Clotting Time) should be performed and an additional bolus of 0.3 mg/kg should be given if needed. GPI administration should be considered in the event that any of the conditions listed in “**CLINICAL TRIALS – REPLACE-2**” is present.

Continuation of the infusion following PCI for up to 4 hours post-procedure is optional, at the discretion of the treating physician. After cessation of the 1.75 mg/kg/h infusion, a reduced infusion dose of 0.25 mg/kg/h may be continued for 4-12 hours as clinically necessary.

BIVALIRUDIN INJECTION is intended for use with ASA (300 – 325 mg daily) and has only been studied in patients receiving concomitant ASA.

In STEMI patients undergoing primary PCI, standard pre-PCI adjunctive therapy should include clopidogrel and may include the early administration of UFH (see **CLINICAL TRIALS – HORIZONS**).

Patients should be carefully monitored following PCI for signs and symptoms consistent with myocardial ischemia.

### **Cardiac Surgery (see Table 1)**

#### **On-pump Cardiac Surgery**

The recommended dosage of BIVALIRUDIN INJECTION is an IV bolus of 1.0 mg/kg immediately followed by a 2.5 mg/kg/h IV infusion. BIVALIRUDIN INJECTION infusion may be terminated approximately 15 minutes prior to the anticipated end of cardiopulmonary bypass (CPB). The ACT may be used to check that the patient is anticoagulated following administration of BIVALIRUDIN INJECTION. Infusion dose adjustment should not be necessary. For patients in whom hemofiltration is required during bypass, periodic ACT monitoring may be used (see **Dosing Pre- and Post-Cardiac Surgery, Medical Management Guidelines for Cardiac Surgery**). If CPB is not terminated within 20 minutes or in patients who need to go back on bypass, a bivalirudin IV bolus of 0.5 mg/kg should be administered and a 2.5 mg/kg/h IV infusion restarted and continued until 15 minutes prior to the anticipated end of CPB (see **DOSAGE AND ADMINISTRATION, Dosing Pre- and Post- Cardiac Surgery, Medical Management Guidelines for Cardiac Surgery** for dosing of the CPB pump with BIVALIRUDIN INJECTION).

#### **Off-pump Cardiac Surgery**

The recommended dosage of BIVALIRUDIN INJECTION is an IV bolus of 0.75 mg/kg immediately followed by a 1.75 mg/kg/h IV infusion for the duration of the procedure. The ACT may be used to check that the patient is anticoagulated following administration of Bivalirudin Injection. In clinical trials, investigators had the option to administer additional boluses of 0.1-0.5 mg/kg or make adjustments to the infusion rate in 0.25 mg/kg/h increments if a higher level of anticoagulation was desired. The data suggest that infusion dose adjustments should not be necessary.

For patients who may need to go on-pump, an additional BIVALIRUDIN INJECTION IV bolus dose of 0.25 mg/kg should be administered to the systemic circulation and the infusion rate should be increased to 2.5 mg/kg/h. In addition, see **Dosing Pre- and Post-Cardiac Surgery, Medical Management Guidelines for Cardiac Surgery** for dosing of the pump.

#### **Dosing Pre- and Post-cardiac Surgery**

BIVALIRUDIN INJECTION may be used for anticoagulation up to 48 hours prior to surgery or in the postoperative phase up to 14 days after the procedure. A BIVALIRUDIN INJECTION IV bolus of 0.1 mg/kg followed by an IV infusion of 0.2 mg/kg/h may be administered, with aPTT monitoring to attain the clinically desired range of 1.5-2.5 times the baseline value.

#### **Medical Management Guidelines for Cardiac Surgery:**

##### **CPB**

Use of BIVALIRUDIN INJECTION for anticoagulation during CPB requires little modification to the conventional bypass circuit setup. Before initiation of CPB, a bolus dose of 50 mg BIVALIRUDIN INJECTION should be added to the circuit regardless of patient weight or volume of the prime. Either an open system or a closed system may be used for venous drainage. A closed system with venous reservoir bags generally has better flow characteristics with more

internal mixing than a hardshell open venous reservoir. After completion of CPB, once it is clear that return to bypass support will not be needed, processing of the remaining circuit volume with a cell saver prior to a readministration to the patient is recommended. Provision to allow recirculation of the circuit following termination from CPB may be provided by administration of 50 mg of BIVALIRUDIN INJECTION to the circuit followed by a continuous infusion of 50 mg/h.

### ***Cardioplegia***

Crystalloid or blood-based cardioplegia may be used. If blood-based cardioplegia is used, blood should be obtained directly from the circuit and, after mixing with cardioplegia solution, should be immediately infused into the coronary system. If there are non-circulating portions of line between the pump and the patient, these lines should be flushed prior to cardioplegia administration. The cardioplegia setup can be circulated continuously by use of a connector. The volume of the cardioplegia circuit is typically 250 mL; for this volume, a continuous infusion of BIVALIRUDIN INJECTION of 6.25 mg/h will maintain anticoagulation within the circuit.

### ***Hemofiltration***

It is recommended that the ACT be measured frequently during hemofiltration to ensure the adequacy of anticoagulation.

### ***Cell Saver***

If a cell saver is used, an anticoagulant is necessary. A citrate-based solution (citrate phosphate dextrose [CPD], acid citrate dextrose [ACD], sodium citrate) is recommended.

### **Dosage Adjustment for Patients with Renal Impairment**

No reduction in the bolus dose of BIVALIRUDIN INJECTION is needed regardless of the patient's baseline renal function.

No infusion dose adjustment is required for patients with mild or moderate renal impairment undergoing either PCI or cardiac surgery. In PCI patients, reduction of the infusion rate to 1.0 mg/kg/h should be considered if the creatinine clearance is less than 30 mL/min. If a PCI patient is dependent on hemodialysis, the infusion rate should be reduced to 0.25 mg/kg/h.

Patients with creatinine clearance below 30 mL/min have not been studied in cardiac surgery. See **ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics** for details regarding bivalirudin pharmacokinetics in patients with renal impairment.

In patients with renal impairment, the ACT should be monitored with any dose alterations. ACT should be checked at 5 and 45 minutes. If the ACT is  $\leq 250$  seconds for renally-impaired patients, administer a second bolus (0.3 mg/kg) and double the infusion rate to maintain the ACT at approximately 350 seconds. If the ACT is 250-300 seconds in renally-impaired patients, re-bolus (0.3 mg/kg) to maintain the ACT approximately 350 seconds. Bivalirudin is hemodialysable (see **ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics**).

### **Use Subsequent to Unfractionated Heparin (UFH) or Low Molecular Weight Heparin (LMWH)**

Patients can be started with BIVALIRUDIN INJECTION 30 minutes after discontinuation of UFH given intravenously, or 8 hours after discontinuation of LMWH given subcutaneously.

### 3.3 Administration

BIVALIRUDIN INJECTION is intended for IV injection and infusion. The dose to be administered is adjusted according to the patient's weight (see **Table 1**).

**Table 1: BIVALIRUDIN INJECTION weight-based dosing table for patients undergoing PCI or cardiac surgery\***

Weight (kg)	Using 5 mg/mL Concentration			
	PCI and Off-Pump Cardiac Surgery		On-Pump Cardiac Surgery	
	Bolus (0.75 mg/kg) (mL)	Infusion (1.75 mg/kg/h) (mL/h)	Bolus (1 mg/kg) (mL)	Infusion (2.5 mg/kg/h) (mL/h)
33-37	5	12	7	18
38-42	6	14	8	20
43-47	7	16	9	23
48-52	7.5	17.5	10	25
53-57	8	19	11	28
58-62	9	21	12	30
63-67	10	23	13	33
68-72	10.5	24.5	14	35
73-77	11	26	15	38
78-82	12	28	16	40
83-87	13	30	17	43
88-92	13.5	31.5	18	45
93-97	14	33	19	48
98-102	15	35	20	50
103-107	16	37	21	53
108-112	16.5	38.5	22	55
113-117	17	40	23	58
118-122	18	42	24	60
123-127	19	44	25	63
128-132	19.5	45.5	26	65
133-137	20	47	27	68
138-142	21	49	28	70
143-147	22	51	29	73
148-152	22.5	52.5	30	75
153-157	23	54	31	78
158-162	24	56	32	80
163-167	25	58	33	83
168-172	25.5	59.5	34	85
173-177	26	61	35	88
178-182	27	63	36	90

Using 5 mg/mL Concentration				
PCI and Off-Pump Cardiac Surgery			On-Pump Cardiac Surgery	
Weight (kg)	Bolus (0.75 mg/kg) (mL)	Infusion (1.75 mg/kg/h) (mL/h)	Bolus (1 mg/kg) (mL)	Infusion (2.5 mg/kg/h) (mL/h)
183-187	28	65	37	93
188-192	28.5	66.5	38	95
193-197	29	68	39	98
198-202	30	70	40	100
203-207	31	72	41	103
208-212	31.5	73.5	42	105
213-217	32	75	43	108
218-222	33	77	44	110
223-227	34	79	45	113

\*If patients have undergone treatment with BIVALIRUDIN INJECTION for ACS prior to PCI and/or CABG, see above for dosing recommendations

BIVALIRUDIN INJECTION should be administered via an intravenous line. No incompatibilities have been observed with administration sets. The following nine drugs should not be administered in the same intravenous line with BIVALIRUDIN INJECTION, since they resulted in haze formation, microparticulate formation, or gross precipitation when mixed with BIVALIRUDIN INJECTION: alteplase, amiodarone HCl, amphotericin B, chlorpromazine HCl, diazepam, prochlorperazine edisylate, reteplase, streptokinase, and vancomycin HCl.

The following six drugs show dose-concentration physical incompatibilities with bivalirudin (i.e. gross precipitation, turbidity changes visible in normal diffuse room light with the unaided eye, increases in measured turbidity, and microprecipitation) during Y-site coadministration at room temperature (23°C): Dobutamine HCl, Famotidine, Haloperidol lactate, Labetalol HCl, Lorazepam, Promethazine HCl. Therefore, the administration of these medicinal products in the same intravenous line as bivalirudin is not recommended.

As with all parenteral drug products, IV mixtures should be inspected visually for clarity, particulate matter, precipitate, discoloration and leakage prior to administration whenever solution and container permit. Solutions showing haziness, particulate matter, precipitate, discoloration or leakage should not be used. Discard unused portion.

#### 4 OVERDOSAGE

Bleeding has been reported in some cases of overdose with single bolus doses of bivalirudin up to 7.5 mg/kg. Discontinuation of BIVALIRUDIN INJECTION (bivalirudin) leads to a gradual reduction in anticoagulant effects due to metabolism of the drug. There has been no experience of overdose in human clinical trials. In case of overdose, BIVALIRUDIN INJECTION should be discontinued, and the patient should be closely monitored for signs of bleeding. Supportive therapy should be instituted, as necessary. There is no known antidote to bivalirudin. Bivalirudin is hemodialysable (see **ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics**).

For management of a suspected drug overdose, contact your regional poison control centre.

## 5 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 2: Dosage forms, strengths, composition and packaging.

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Intravenous injection	5 mg/mL	Glacial acetic acid, Polyethylene glycol, Sodium acetate trihydrate, Sodium hydroxide and Water for injection

BIVALIRUDIN INJECTION (bivalirudin) is supplied as a refrigerated, ready-to-use, clear to slightly opalescent, colorless to slightly yellow, sterile solution in single-use glass vials.

Each 50 mL vial of BIVALIRUDIN INJECTION contains 250 mg (5 mg/mL) of bivalirudin and the following non-medicinal ingredients: sodium acetate trihydrate, polyethylene glycol (400), bound trifluoroacetate (0.4 to 0.6 mg/mL), water for injection and glacial acetic acid and/or sodium hydroxide to adjust pH to 5.0 - 5.5. The solution is intended for intravenous use at room temperature.

Packaging: Cartons of 1 or 10 vials.

## 6 WARNINGS AND PRECAUTIONS

### General

**BIVALIRUDIN INJECTION (bivalirudin) should not be administered intramuscularly.**

There is no known antidote to bivalirudin. Bivalirudin is hemodialysable (see **ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics**).

### **Acute Stent Thrombosis**

Acute stent thrombosis (<24 hours) has been observed in patients with STEMI undergoing primary PCI and has been managed by Target Vessel Revascularisation (TVR) (see **ADVERSE REACTIONS, HORIZONS**; and **CLINICAL TRIALS, HORIZONS**). Patients should remain for at least 24 hours in a facility capable of managing ischemic complications and should be carefully monitored following primary PCI for signs and symptoms consistent with myocardial ischemia.

An increased incidence of acute stent thrombosis has been mainly observed in STEMI patients undergoing primary PCI. The majority of these cases were non-fatal. This increased risk of acute stent thrombosis was observed during the first 4 hours following the end of the procedure among patients who either discontinued the infusion of bivalirudin at the end of the procedure or received a continued infusion at the reduced dose of 0.25 mg/kg/hour.

## **Brachytherapy**

To date, no formal clinical trials have been conducted with bivalirudin as the principal anticoagulant when performing catheter-based brachytherapy (beta or gamma) to reduce the risk of in-stent restenosis. Therefore, BIVALIRUDIN INJECTION is not recommended for use in brachytherapy procedures.

An increased risk of thrombus formation has been associated with the use of bivalirudin in gamma brachytherapy, including fatal outcomes.

## **Cardiac Surgery**

When bivalirudin is used in cardiac surgery, techniques that allow blood or blood-based solutions to lie stagnant should be avoided. Local bivalirudin levels may decrease due to metabolism by proteases from blood exposed to wound or foreign surfaces, potentially leading to local clot formation. During surgery, blood should not be allowed to stand in grafts, and grafts should preferably be stored and tested for flow and leakage with saline, instead of blood. Care should be taken to avoid stasis in the internal mammary artery after harvest. Circulation throughout the cardiopulmonary bypass (CPB) circuit must be ensured with particular attention paid to bypass lines that are blood-filled and then clamped off, or lines that are intermittently used for perfusion.

## **Hematologic**

### **Hemorrhage**

Bleeding may occur in conjunction with use of any anticoagulant drug. As with other anticoagulants, bivalirudin should be used with extreme caution in patients at increased risk of hemorrhage. Bleeding can occur at any site during therapy with BIVALIRUDIN INJECTION. An unexpected drop in hematocrit or blood pressure should lead to a search for a bleeding site (see **DRUG INTERACTIONS**; and **ADVERSE REACTIONS, Bleeding**).

## **Immune**

### **Immunogenicity/Re-exposure**

In *in vitro* studies, bivalirudin exhibited no platelet aggregation response against sera from patients with a history of HIT/TS.

Among 494 patients who received bivalirudin in clinical trials and were tested for antibodies, two had treatment-emergent positive bivalirudin antibody tests. Neither patient demonstrated clinical evidence of allergic or anaphylactic reactions, and repeat testing was not performed. Nine other patients who had initial positive tests were negative on repeat testing. Of fifteen healthy volunteers who were exposed to bivalirudin twice, none developed antibodies.

## **Laboratory Test Interference**

Bivalirudin affects International Normalized Ratio (INR), therefore INR measurements made in patients who have been treated with BIVALIRUDIN INJECTION may not be useful for determining the appropriate dose of warfarin.

## **6.1 Special Populations**

### **6.1.1 Pregnant Women**

There are no studies available evaluating bivalirudin in pregnant women.

Studies in rats and rabbits have demonstrated no evidence of impaired fertility or harm to the fetus attributable to bivalirudin at clinically relevant doses. Because animal reproduction studies are not always predictive of human response, bivalirudin should be used during pregnancy only if clearly indicated.

In PCI, bivalirudin is intended for use with ASA (see **INDICATIONS**). Because of possible adverse effects on the neonate and the potential for increased maternal bleeding, particularly during the third trimester, bivalirudin and ASA should be used together during pregnancy only with caution and if benefit is thought to outweigh risk.

### **6.1.2 Breast-feeding**

It is not known whether bivalirudin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when BIVALIRUDIN INJECTION is administered to a nursing woman.

### **6.1.3 Pediatrics**

The safety and efficacy of bivalirudin in children have not been established.

### **6.1.4 Geriatrics**

Across studies approximately 45% of patients were  $\geq 65$  years of age and 18% of patients were  $\geq 75$  years old. Elderly patients experienced more bleeding events than younger patients.

## **7 ADVERSE REACTIONS**

### **7.1 Adverse Reaction Overview**

As with any antithrombotic treatment, hemorrhagic manifestations can occur. Risk factors for bleeding identified with the use of bivalirudin include elderly status, female gender, and the concomitant use of drugs known to cause bleeding, such as heparin, warfarin and thrombolytics. These risks are comparable to those seen in heparin-treated patients. Petechiae or easy bruising may precede frank hemorrhage. The early signs of bleeding may include epistaxis, hematuria, or melena. Bleeding may occur at any site and be difficult to detect, for example, retroperitoneal bleeding. Bleeding may also occur at surgical sites. Major hemorrhage, including retroperitoneal or intracranial bleeding, has been associated with bivalirudin use, in some cases leading to a fatal outcome.

### **ACUITY (UA/NSTEMI)**

The type and severity of adverse events observed in the ACS trials were similar between the bivalirudin and other treatment groups, and were typical of ACS trials. Few patients discontinued due to an adverse event, and the overall incidence and types of events that led to discontinuation were balanced between treatment groups. Very few of these events were associated with bleeding.

### **HORIZONS (STEMI undergoing primary PCI)**

During the first 30 days of the study, 0.7% of bivalirudin patients and 0.6% of heparin patients reported a serious adverse event leading to study discontinuation. The types of events reported in each arm were similar and the one adverse event reported by  $>0.1\%$  of patients in either treatment arm was cardiogenic shock.

## REPLACE-2 (PCI)

Adverse events observed in clinical trials are similar between the bivalirudin-treated patients and the control groups. Adverse events seen are those typical of PCI trials. In clinical trials, adverse events leading to discontinuation occurred in 2% of bivalirudin patients and 7% of heparin patients.

## CHOOSE and EVOLUTION (Cardiac Surgery)

Pleural effusion, atelectasis and atrial fibrillation were the most frequent adverse events observed in the clinical trials in both the bivalirudin group and the control group; these events are common following cardiac surgery.

### 7.2 Clinical Trial Adverse Reactions

Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

### Bleeding

#### ACUITY (UA/NSTEMI)

In 13,819 patients with ACS treated in the ACUITY trial, patients administered bivalirudin monotherapy exhibited statistically significantly lower rates of bleeding, and transfusions when compared to those patients who received heparin+GPI (Glycoprotein IIb/IIIa Inhibitor). There was no statistical difference in bleeding rates when bivalirudin+GPI was compared to heparin + GPI (Table 3).

Table 3: Bleeding rates ACUITY study

	Bivalirudin <sup>1</sup> alone (N=4,612)	Bivalirudin + GPI (N=4,606)	Heparin* + GPI* (UFH or enoxaparin) (N=4,603)
<b><u>ACUITY – defined bleeding</u></b>			
Major <sup>2</sup>	3.0%	5.3%	5.7%
Minor <sup>3</sup>	12.9%	21.8%	21.6%
<b><u>TIMI – defined bleeding<sup>4</sup></u></b>			
Major	0.9%	1.6%	1.9%
Minor	3.7%	6.1%	6.4%
<b>Transfusions</b>	1.6%	2.6%	2.7%

<sup>1</sup> GPIs were administered to <7% of patients in the bivalirudin group for procedural complications.

<sup>2</sup> Defined as the occurrence of any of the following: intracranial bleeding, retroperitoneal bleeding, intraocular bleeding, a transfusion of any units of blood/blood products, a fall in haemoglobin (Hgb)  $\geq 4$  g/dL, whether or not bleeding site is identified, spontaneous or non-spontaneous blood loss with a decrease in Hgb  $\geq 3$  g/dL, reoperation for bleeding, access site bleeding requiring surgical or radiological intervention, or a hematoma  $\geq 5$  cm at puncture site.

<sup>3</sup> Defined as observed bleeding that does not meet the criteria for major bleeding.

<sup>4</sup> Thrombolysis in Myocardial Infarction (TIMI) major bleeding is defined as: intracranial, or a fall in adjusted Hgb  $>5$  g/dL or hematocrit (Hct) of  $>15\%$ ; TIMI minor bleeding is defined as a fall in adjusted Hgb of 3 to  $<5$  g/dL or a fall in adjusted Hct of 9 to  $<15\%$ , with a bleeding site such as hematuria, hematemesis, hematomas, retroperitoneal bleeding or a decrease in Hgb of  $>4$  g/dL with no bleeding site.

\* Heparin was either unfractionated heparin (UFH) or enoxaparin.

## HORIZONS (STEMI undergoing primary PCI)

The following adverse reaction data are based on a clinical study of bivalirudin in patients with STEMI undergoing PCI; 1,800 patients were randomized to receive bivalirudin alone, 1,802 were randomized to unfractionated heparin plus GP IIb/IIIa inhibitor. The major bleeding rate (ACUITY-scale) in the bivalirudin arm was statistically superior compared to rate in the unfractionated heparin plus GP IIb/IIIa arm ( $p < 0.0001$ ) (**Table 4**). Major bleeding occurred most frequently at the sheath puncture site. The most frequent event was a haematoma <5 cm at puncture site. Thrombocytopenia was reported in 26 (1.6%) of bivalirudin-treated patients and in 67 (3.9%) of patients treated with unfractionated heparin + GP IIb/IIIa inhibitor.

**Table 4: Bleeding rates HORIZONS study**

	Bivalirudin (N=1,800)	Heparin* + GPI* (UFH or enoxaparin) (N=1,802)
<b><u>ACUITY – defined bleeding</u></b>		
Major <sup>1</sup>	5.1%	8/8%
<b><u>TIMI – defined bleeding<sup>4</sup></u></b>		
Major <sup>2</sup>	1.8%	3.2%
Minor <sup>3</sup>	2.3%	4.3%
<b><u>GUSTO – defined bleeding<sup>4</sup></u></b>		
Severe/Life-threatening	0.5%	0.6%
Moderate	3.2%	5.2%
Mild	3.4%	5.8%

<sup>1</sup> Defined as the occurrence of any of the following: intracranial bleeding, intraocular bleeding, retroperitoneal bleeding, access site haemorrhage requiring surgery or a radiologic or interventional procedure, haematoma  $\geq 5$  cm in diameter at the puncture site, reduction in haemoglobin concentration of  $\geq 4$  g/dL without an overt source of bleeding, reduction in haemoglobin concentration of  $\geq 3$  g/dL with overt bleeding, re-operation for bleeding, or any blood product transfusion.

<sup>2</sup> Thrombolysis in Myocardial Infarction (TIMI) major bleeding is defined as: Intracranial bleeding or bleeding associated with a decrease in haemoglobin  $\geq 5$  g/dL (or  $\geq 15\%$  of haematocrit).

<sup>3</sup> TIMI minor bleeding is defined as: Observed bleeding:  $\geq 3$  g/dL decrease in the haemoglobin concentration (or  $\geq 9\%$  decrease in haematocrit); No bleeding observed:  $\geq 4$  g/dL decrease in the haemoglobin concentration (or  $\geq 12\%$  decrease in haematocrit)

<sup>4</sup> Global use of strategies to open occluded coronary arteries (GUSTO) bleeding defined as: Severe or life-threatening: Either intracranial haemorrhage or bleeding that causes haemodynamic compromise and requires intervention; Moderate: Bleeding that requires blood transfusion but does not result in haemodynamic compromise.

## REPLACE-2 (PCI) and BAT (PTCA)

In 6,010 patients undergoing PCI treatment in a double-blind trial, bivalirudin patients plus provisional GPI (7.2%; see **CLINICAL TRIALS**) exhibited statistically significant lower rates of bleeding, transfusions, and thrombocytopenia than patients receiving heparin plus a glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitor, as noted in **Table 5**. Major bleeding was seen in 2.4% of patients treated with bivalirudin+GPI compared to 4.1% in the patients treated with heparin+GPI.

**Table 5: Major hematologic outcomes REPLACE-2 study (safety population)**

	Bivalirudin (N=2,914)	Heparin+GPIIb/IIIa (N=2,987)	P Value
<b><u>% Patients with Major Hemorrhage<sup>1</sup></u></b>	2.3%	4.0%	<0.001
<b><u>Non-Access Site Bleeding:</u></b>			
Retroperitoneal Bleeding	0.2%	0.5%	0.069

Intracranial Bleeding	<0.1%	0.1%	1
Required Transfusion (any)	1.5%	2.5%	0.009
<b>Access Site Bleeding:</b>			
Sheath Site Bleeding	0.9%	2.4%	<0.001
<b>% Patients with Minor Hemorrhage<sup>2</sup></b>	13.6%	25.8%	<0.001
<b>TIMI – Definition Bleeding<sup>3</sup></b>			
Major and Minor	1.9%	3.8%	<0.001
<b>Thrombocytopenia<sup>4</sup></b>			
< 100,000 mm <sup>3</sup>	0.7%	1.7%	<0.001
< 50,000 mm <sup>3</sup>	0.3%	0.6%	0.039

<sup>1</sup> Defined as the occurrence of any of the following: intracranial bleeding, retroperitoneal bleeding, a transfusion  $\geq 2$  units of blood/blood products, a fall in hemoglobin  $>4$  g/dL, whether or not bleeding site is identified, spontaneous or non-spontaneous blood loss with a decrease in hemoglobin  $\geq 3$  g/dL.

<sup>2</sup> Defined as observed bleeding that does not meet the criteria for major hemorrhage.

<sup>3</sup> Defined as: intracranial, a fall in adjusted Hgb  $>5$  g/dL, spontaneous gross hematuria or hematemesis, bleeding associated with a fall in adjusted Hgb  $>3$  g/dL, a fall in adjusted Hgb  $>4$ g/dL with no bleeding.

<sup>4</sup> If platelets  $<100,000$  and  $>25\%$  reduction from baseline, or  $<50,000$ .

In two randomised, double-blind studies that evaluated 4,312 patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA), bivalirudin patients exhibited lower rates of major bleeding and lower requirements for blood transfusions than patients treated with heparin (**Table 6**). It should be noted that the comparator dose of heparin used in these studies was 175 IU/kg, a dose significantly higher than generally used currently (see **CLINICAL TRIALS**).

**Table 6: Major bleeding and transfusions in BAT trial: All patients<sup>1</sup> during hospitalization period**

	<b>Bivalirudin (N=2,161)</b>	<b>Heparin (N=2,151)</b>
<b>Number (%) of Patients with Major Hemorrhage<sup>2</sup></b>	79 (3.7)	199 (9.3)
- with $\geq 3$ g/dL fall in Hgb	41 (1.9)	124 (5.8)
- with $\geq 5$ g/dL fall in Hgb	14 ( $<1$ )	47 (2.2)
- Retroperitoneal Bleeding	5 ( $<1$ )	15 ( $<1$ )
- Intracranial Bleeding	1 ( $<1$ )	2 ( $<1$ )
- Required Transfusion	43 (2.0)	123 (5.7)

<sup>1</sup> No monitoring of ACT (or PTT) was done after a target ACT was achieved.

<sup>2</sup> Major hemorrhage was defined as the occurrence of any of the following: intracranial bleeding, retroperitoneal bleeding, clinically overt bleeding with a decrease in hemoglobin  $\geq 3$ g/dL or leading to a transfusion of  $\geq 2$  units of blood. This table includes data from entire hospital period.

### **CHOOSE and EVOLUTION (Cardiac Surgery)**

In the CHOOSE and EVOLUTION studies the incidence of blood product transfusions was lower in the bivalirudin treatment group (**Table 7**). The incidence of major bleeding and median total postoperative blood loss volumes were similar.

**Table 7: Summary of bleeding related safety data at day 7/discharge in the CHOOSE studies and in pooled on- and off-pump studies in cardiac surgery (safety population)**

Parameter	CHOOSE Studies (HIT/TS) <sup>1</sup>				Pooled Studies (HIT/TS and Non-HIT/TS) <sup>1</sup>			
	On-pump		Off-pump		On-pump		Off-pump	
	Bivalirudin N = 49 n (%)	Historical control N = 75 n (%)	Bivalirudin N = 51 n (%)	Historical control N = 36 n (%)	Bivalirudin N = 147 n (%)	Heparin/ protamine N = 121 n (%)	Bivalirudin N = 152 n (%)	Heparin/ Protamine N = 88 n (%)
Incidence of transfusions	41 (83.7)	69 (92.0)	27 (52.9)	32 (88.9)	98 (66.7)	94 (77.7)	73 (48.0)	61 (69.3)
Patients with major bleeding events	2 (4.1)	6 (8.0)	2 (3.9)	3 (8.3)	8 (5.4)	6 (5.0)	11 (7.2)	5 (5.7)
Patients with persistent hemorrhage requiring repeat operation	2 (4.1)	4 (5.3)	2 (3.9)	3 (8.3)	8 (5.4)	5 (4.1)	10 (6.6)	5 (5.7)
Median total postoperative blood loss (mL) up to 24 hours	N=47 880.0	N=62 797.5	N=51 780.0	N=35 990.0	N=143 815.0	N=106 750.0	N=131 713.0	N=75 750.0

<sup>1</sup> 10 historical patients from the CHOOSE studies were administered an anticoagulant other than heparin/protamine and are excluded from this analysis.

## **Other Adverse Reactions**

### **ACUITY (UA/NSTEMI)**

In 13,819 patients with UA/NSTEMI in the ACUITY study, those treated with bivalirudin had similar rates of non-bleeding adverse events compared to the patients who received heparin plus GPI. No individual adverse reaction occurred with a frequency higher than 0.1% in the bivalirudin population.

### **HORIZONS (STEMI undergoing primary PCI)**

In the HORIZONS study, 55.1% of all patients receiving bivalirudin experienced at least one adverse event and 8.7% experienced an adverse drug reaction. The most frequently reported adverse events were the same in both treatment arms and included hypotension, ventricular tachycardia, chest pain, and bradycardia.

**Table 8** summarizes the most frequently reported (in >2% of patients in either treatment arm) individual adverse events during the first 30 days of the HORIZONS study, irrespective of relationship to study drug. None of the adverse events were reported by more than 8% of patients in the safety population.

The incidence of stent thrombosis within the first 24 hours was 1.5% in patients receiving bivalirudin *versus* 0.3% in patients receiving unfractionated heparin plus GP IIb/IIIa inhibitor ( $p=0.0002$ ). Two deaths occurred after acute stent thrombosis, 1 in each arm of the study. The incidence of stent thrombosis between 24 hours and 30 days was 1.2% in patients receiving bivalirudin *versus* 1.9% in patients receiving unfractionated heparin plus GP IIb/IIIa inhibitor ( $p=0.1481$ ). A total of 17 deaths occurred after subacute stent thrombosis, 3 in the bivalirudin arm and 14 in the UFH plus GP IIb/IIIa arm. There was no statistically significant difference in the rates of stent thrombosis between the two arms at 30 days ( $p=0.3257$ ) and 1 year ( $p=0.7754$ ).

**Table 8: Adverse events reported by >2% of patients in either treatment arm in the HORIZONS study (safety population)**

Preferred Term	Number (%) of patients		
	Bivalirudin (N = 1,749)	UFH + GP IIb/IIIa (N = 1,818)	Total (N = 3,567)
<b>Any AE</b>	<b>964 (55.1)</b>	<b>1,060 (58.3)</b>	<b>2,024 (56.7)</b>
Hypotension	134 (7.7)	142 (7.8)	276 (7.7)
Ventricular tachycardia	109 (6.2)	122 (6.7)	228 (6.4)
Chest pain	114 (6.5)	114 (6.3)	228 (6.4)
Bradycardia	82 (4.7)	97 (5.3)	179 (5.0)
Atrial fibrillation	67 (3.8)	87 (4.8)	154 (4.3)
Haematoma	42 (2.4)	87 (4.8)	129 (3.6)
Ventricular fibrillation	68 (3.9)	57 (3.1)	125 (3.5)
Haemorrhage	38 (2.2)	75 (4.1)	113 (3.2)
Back pain	44 (2.5)	59 (3.2)	103 (2.9)
Headache	50 (2.9)	55 (3.0)	105 (2.9)
Cardiac failure	56 (3.2)	48 (2.6)	104 (2.9)
Nausea	42 (2.4)	52 (2.9)	94 (2.6)
Pyrexia	37 (2.1)	48 (2.6)	85 (2.4)
Haemoglobin decreased	39 (2.2)	50 (2.8)	89 (2.5)
Cardiovascular disorder	48 (2.7)	31 (1.7)	79 (2.2)
Injection site haemorrhage	24 (1.4)	52 (2.9)	76 (2.1)
Reperfusion injury	40 (2.3)	28 (1.5)	68 (1.9)
Anaemia	24 (1.4)	39 (2.1)	63 (1.8)

**REPLACE-2 (PCI) and BAT (PTCA)**

In the REPLACE-2 trial similar non-bleeding adverse events were reported in the two treatment groups as shown below in **Table 9**:

**Table 9: Adverse events other than bleeding occurring in ≥ 2% of patients in either treatment group in REPLACE-2**

Event	Treatment Group	
	Bivalirudin (N = 2,914)	Heparin + GP IIb/IIIa (N = 2,987)
<b>Number of Patients (%)</b>		
<b>Cardiovascular</b>		
Hypotension	91 (3.1)	120 (4.0)
Angina Pectoris	155 (5.3)	156 (5.2)
<b>Gastrointestinal</b>		
Nausea	86 (3.0)	96 (3.2)
<b>Miscellaneous</b>		
Back pain	268 (9.2)	263 (8.8)
Pain	98 (3.4)	72 (2.4)
Chest Pain	68 (2.3)	69 (2.3)
Headache	75 (2.6)	83 (2.8)
Injection site pain	80 (2.7)	80 (2.7)

All adverse events other than bleeding reported for  $\geq 5\%$  of patients in either treatment group in the BAT trial are shown below in **Table 10**.

**Table 10: Adverse events other than bleeding occurring in  $\geq 5\%$  of patients in either treatment group in BAT trial**

Event	Treatment Group	
	Bivalirudin (N = 2161)	Heparin (N = 2151)
	<b>Number of Patients (%)</b>	
<b>Cardiovascular</b>		
Hypotension	262 (12)	371 (17)
Hypertension	135 (6)	115 (5)
Bradycardia	118 (5)	164 (8)
<b>Gastrointestinal</b>		
Nausea	318 (15)	347 (16)
Vomiting	138 (6)	169 (8)
Dyspepsia	100 (5)	111 (5)
<b>Genitourinary</b>		
Urinary retention	89 (4)	98 (5)
<b>Miscellaneous</b>		
Back pain	916 (42)	944 (44)
Pain	330 (15)	358 (17)
Headache	264 (12)	225 (10)
Injection site pain	174 (8)	274 (13)
Insomnia	142 (7)	139 (6)
Pelvic pain	130 (6)	169 (8)
Anxiety	127 (6)	140 (7)
Abdominal pain	103 (5)	104 (5)
Fever	103 (5)	108 (5)
Nervousness	102 (5)	87 (4)

### **CHOOSE and EVOLUTION (Cardiac Surgery)**

All adverse events other than bleeding reported for  $\geq 5\%$  of patients in either treatment group are shown below in **Table 11**. Adverse events were not collected for the historical cohort in the CHOOSE studies. Prolongations of activated partial thromboplastin time (aPTT) and prothrombin time (PT) were reported more frequently in the bivalirudin group. This is expected with bivalirudin due to absence of a reversal agent, and was reported as an adverse event by a single site. All other differences in adverse event rates that were statistically significant occurred in the heparin/protamine group.

**Table 11: Adverse events other than bleeding occurring in ≥5% of patients in either treatment group in the pooled cardiac surgery studies**

<b>Adverse event</b>	<b>Bivalirudin N = 379</b>	<b>Heparin/protamine<sup>1</sup> N = 158</b>
<b>Number of patients with any common adverse event</b>	256 (67.5)	115 (72.8)
Pleural effusion	94 (24.8)	55 (34.8)
Atrial fibrillation	59 (15.6)	28 (17.7)
Atelectasis	49 (12.9)	37 (23.4)
Nausea	44 (11.6)	29 (18.4)
Anaemia NOS	41 (10.8)	15 (9.5)
Hypotension NOS	34 (9.0)	12 (7.6)
Activated partial thromboplastin time	26 (6.9)	0 (0.0)
Pain NOS	26 (6.9)	23 (14.6)
Oedema peripheral	26 (6.9)	12 (7.6)
Prothrombin time prolonged	24 (6.3)	0 (0.0)
Pericardial effusion	23 (6.1)	12 (7.6)
Constipation	21 (5.5)	13 (8.2)
Wound secretion	20 (5.3)	19 (12.0)
Oliguria	20 (5.3)	12 (7.6)
Vomiting NOS	18 (4.7)	13 (8.2)
Anxiety	15 (4.0)	14 (8.9)
Hypertension NOS	13 (3.4)	8 (5.1)
Chest pain	12 (3.2)	10 (6.3)

<sup>1</sup> Does not include data from the historical cohort of the CHOOSE studies

### 7.3 Less Common Clinical Trial Adverse Reactions

Rarely, the following have been reported with bivalirudin use, without attribution to cause: thrombocytopenia, urticaria, rash.

### 7.4 Post-Market Adverse Reactions

The following events have been reported: fatal bleeding; hypersensitivity and allergic reactions including very rare reports of anaphylaxis; thrombus formation during PCI with and without intracoronary brachytherapy, including reports of fatal outcomes, respiratory tract hemorrhages, cardiac tamponade and INR increased.

## 8 DRUG INTERACTIONS

### 8.1 Overview

In clinical trials in patients undergoing PCI, coadministration of bivalirudin with heparin, warfarin or thrombolytics was associated with increased risk of major bleeding events compared to patients not receiving these concomitant medications.

The safety and effectiveness of bivalirudin have not been formally established when used in conjunction with GPIIb/IIIa inhibitors. In two clinical trials, however, it was noted that the apparent bleeding advantage of bivalirudin over heparin plus planned GPIIb/IIIa inhibitor

(Table 3, Table 5, Table 15; see also **ADVERSE REACTIONS, Bleeding**) was practically nullified when a GPIIb/IIIa inhibitor was added to bivalirudin therapy.

No formal drug interaction studies have been carried out with bivalirudin. Clinical studies evaluating pharmacodynamic effects and providing preliminary safety information of various products when used in combination with bivalirudin have been carried out, including the adenosine diphosphate antagonist, ticlopidine, and the GPIIb/IIIa inhibitors, abciximab, tirofiban and eptifibatide. Although data are limited, precluding conclusions regarding efficacy and safety in combination with these agents, the results do not suggest interaction between Bivalirudin Injection (bivalirudin) and the individual drugs studied in respect of their pharmacodynamic activities. These results are not sufficient to conclude definitively that no interaction exists.

## 9 ACTION AND CLINICAL PHARMACOLOGY

### 9.1 Mechanism of Action

Bivalirudin is a specific and reversible direct thrombin inhibitor. The active substance is a synthetic peptide composed of twenty amino acids. Bivalirudin directly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, which allows fibrin to develop a covalently cross-linked framework, thus stabilising formed thrombus. Thrombin also activates Factors V and VIII, promoting further thrombin generation; and activates platelets, stimulating aggregation and granule release. The binding of bivalirudin to thrombin is reversible as thrombin slowly cleaves the bivalirudin- Arg3-Pro4 bond, resulting in recovery of thrombin active site functions.

In *in vitro* studies, bivalirudin inhibited both soluble (free) and clot-bound thrombin and was not neutralized by products of the platelet release reaction. The clinical relevance of these findings is unknown. It also prolonged the aPTT, thrombin time (TT), and PT of normal human plasma in a concentration-dependent manner.

### 9.2 Pharmacodynamics

In healthy volunteers and patients undergoing routine angioplasty, bivalirudin exhibits linear dose-dependent and concentration-dependent anticoagulant activity as evidenced by prolongation of the ACT, aPTT, PT, and TT. Intravenous administration of bivalirudin produces a prompt anticoagulant effect. Coagulation times return to the normal range approximately 1-2 hours following cessation of bivalirudin administration in patients with normal renal function.

In 291 patients undergoing routine angioplasty, a positive correlation was observed between the dose of bivalirudin and the proportion of patients achieving ACT values of 300 or 350 seconds. In the subset of patients receiving bivalirudin at a dose of 1.0 mg/kg IV bolus plus 2.5 mg/kg/h IV infusion for 4 hours, then followed by 0.2 mg/kg/h, all patients reached maximal ACT values > 300 seconds.

The correlation of various clotting tests with bivalirudin plasma concentration was studied in patients undergoing cardiac surgery. The data confirmed that, as during PCI, the activated clotting times were prolonged in a concentration-dependent manner during cardiac surgery.

An *in-vitro* study of the pharmacodynamic effects of a liquid formulation of bivalirudin (BIVALIRUDIN INJECTION) and a lyophilized formulation of bivalirudin on the activated partial thromboplastin time (aPTT), the thrombin time (TT) and the prothrombin time (PT) has been conducted over therapeutic concentration ranges in Male and Female Human Plasma samples.

The results of the *in-vitro* study demonstrate that BIVALIRUDIN INJECTION liquid formulation is equivalent to the lyophilized formulation of bivalirudin in terms of its pharmacodynamic activity, as measured by PT, aPTT, and TT at all concentrations tested over the therapeutic range.

### 9.3 Pharmacokinetics

**Human Pharmacokinetics:** In healthy volunteers, bivalirudin was administered as a 15-minute IV infusion at a range of doses.

**Table 12: Bivalirudin IV infusion in healthy volunteers over 15 minutes**

Infusion Dose (mg/kg/h)	Mean Volume of Distribution (L/kg)	Mean Clearance (mL/min/kg)	Mean Half-Life (min)	Mean Percentage Urinary Excretion (%)
0.2	N/D	N/D	N/D	N/D
0.3	N/D	N/D	N/D	N/D
0.6	N/D	N/D	N/D	N/D
1.2	0.24	7.79	22.5	9.9
2.4	0.24	6.74	24.6	13.4

N/D: not detectable

Bivalirudin plasma concentrations were measured using an ELISA antibody based assay that detected bivalirudin and some bivalirudin metabolites.

**Absorption:** Bivalirudin exhibits linear pharmacokinetics following IV administration to patients undergoing PTCA. In these patients, a mean steady state bivalirudin concentration of  $12.3 \pm 1.7$  mcg/mL is achieved after administration of an IV bolus of 1 mg/kg followed by a 2.5 mg/kg/h IV infusion given for 4 hours.

**Distribution:** Bivalirudin does not bind to plasma proteins other than thrombin, or to red blood cells.

**Excretion:** Bivalirudin is cleared from plasma by a combination of renal mechanisms and proteolytic cleavage, with a half-life in patients with normal renal function of about 25 minutes. Bivalirudin is hemodialysable, with approximately 25% cleared by hemodialysis.

### Special Populations and Conditions

**Renal Insufficiency:** The disposition of bivalirudin was also studied in PTCA patients with mild and moderate renal impairment and in patients with severe renal impairment. Drug elimination was related to glomerular filtration rate (GFR), see **Table 13**.

**Table 13: Pharmacokinetics in patients with renal impairment\***

Renal Function (GFR, mL/min)	Clearance (mL/min/kg)	Half-life (minutes)
Normal renal function ( $\geq 90$ mL/min)	3.4	25

Renal Function (GFR, mL/min)	Clearance (mL/min/kg)	Half-life (minutes)
Mild renal impairment (60-89 mL/min)	3.4	22
Moderate renal impairment (30-59 mL/min)	2.7	34
Severe renal impairment (10-29 mL/min)	2.8	57
Dialysis-dependent patients (off dialysis)	1.0	3.5 hours

\*The ACT should be monitored in renally-impaired patients.

Further studies have been carried out in patients with varying degrees of renal impairment undergoing PTCA at the dose of 1.0 mg/kg IV bolus, plus 2.5 mg/kg/h IV infusion for 4 hours followed by 0.5 mg/kg/h for a further 4 hours, and in severely renally impaired patient volunteers where a bolus of 1.0 mg/kg and infusion of 0.5 mg/kg/h for 10 hours was given, see **Table 14** below. Plasma and urine levels of bivalirudin were detected by an LC/MS based method validated to quantify only intact bivalirudin.

**Table 14: Pharmacokinetics of bivalirudin in healthy volunteers and patients with renal impairment**

Renal Function	IV Infusion Dose (mg/kg/h)	Mean Clearance (mL/min/kg)	Elimination Half-Life (min)
Normal Renal Function GFR ≥ 90 mL/min	2.5 (4 h)	3.4 ± 0.5	24.9 ± 12.1 (modeled)
	0.5 (4 h)	3.7 ± 1.0	
Mild Renal Impairment GFR 60-89 mL/min	2.5 (4 h)	3.4 ± 0.7	22.2 ± 8.0 (modeled)
	0.5 (4 h)	3.2 ± 0.9	
Moderate Renal Impairment GFR 30-59 mL/min	2.5 (4 h)	2.7 ± 0.4	33.5 ± 6.8 (modeled)
	0.5 (4 h)	2.5 ± 0.2	
Severe Renal Impairment GFR <30 mL/min	0.5 (10 h)	2.8 ± 0.7	56.8 ± 24.0

These data indicate that patients with moderate and severe renal impairment exhibit about 20% reduction in renal clearance. The half-life was prolonged in these patients. Therefore, in patients with severe renal impairment (GFR <30 mL/min), ACT should be monitored and a reduction in the infusion dose should be considered (see **DOSAGE AND ADMINISTRATION, Dosage Adjustment for Patients with Renal Impairment**).

An additional study of subjects with normal to severely impaired renal function (as determined by insulin clearance), demonstrated that plasma clearance of bivalirudin is proportional to glomerular filtration rate at all levels of renal function. The study also demonstrated that bivalirudin is hemodialysable.

For patients with renal impairment, the ACT should be monitored. In patients with renal impairment, the initial bolus dose should not be adjusted, however a reduction of the infusion dose to be administered may be required (see **DOSAGE AND ADMINISTRATION, Dosage Adjustments for Patients with Renal Impairment**).

**Cardiac Surgery:** In a population of patients undergoing cardiac surgery utilizing CPB with normal renal function or mild/moderate renal dysfunction at baseline, the mean plasma bivalirudin concentration 5 minutes after administration of an IV bolus dose of 1.0 mg/kg followed by a 2.5 mg/kg/h IV infusion was 13.3 ± 2.4 mcg/mL. Bivalirudin levels were maintained

at or above this concentration for the duration of infusion. Bivalirudin was eliminated with a clearance of 198 mL/min (2.34 mL/min/kg). Following termination of infusion, plasma bivalirudin concentrations declined biexponentially with an initial half-life of 27 minutes and a terminal half-life of 77 minutes. Temperature had no detectable effect on bivalirudin clearance. The clearance of bivalirudin was reduced by 20-30% in patients with mild or moderate renal impairment. The pharmacokinetics of bivalirudin in off-pump cardiac surgery patients was similar to that in on-pump surgery patients.

## **10 STORAGE, STABILITY AND DISPOSAL**

BIVALIRUDIN INJECTION (bivalirudin) vials are to be shipped and stored under refrigerated conditions (2 - 8°C). Do not freeze.

BIVALIRUDIN INJECTION may be stored at room temperature for up to 72 hours.

Discard any unused portion of solution remaining in the vial.

## PART II: SCIENTIFIC INFORMATION


### 11 PHARMACEUTICAL INFORMATION

#### Drug Substance

Bivalirudin is a synthetic peptide with the following attributes:

Proper name:	Bivalirudin
Chemical name:	D-phenylalanyl-L-prolyl-L-arginyl-L-prolyl-glycyl-glycyl-glycyl-glycyl-L-asparagyl-glycyl-L-aspartyl-L-phenylalanyl-L-glutamyl-L-glutamyl-L-isoleucyl-L-prolyl-L-glutamyl-L-glutamyl-L-tyrosyl-L-leucine trifluoroacetate (salt) hydrate
Molecular formula and molecular mass:	$C_{98}H_{138}N_{24}O_{33} \cdot (C_2HF_3O_2)_x \cdot (H_2O)_y$ 2180 daltons (anhydrous free base peptide)

Structural formula:



Physicochemical properties: Bivalirudin is a white to off-white powder, with a pH of approximately 3 when dissolved in water without buffering.

The compound's solubility is  $\geq 140$  mg/mL at pH 4.6-5.6.

Bivalirudin is insoluble ( $\leq 0.1$  mg/mL) in acetonitrile, chloroform, octanol and ethyl acetate. It is sparingly soluble ( $\geq 0.1$  mg/mL,  $\leq 1.0$  mg/mL) in acetone and sec-butanol, and soluble ( $\geq 1.0$  mg/mL,  $\leq 10.0$  mg/mL) in water, pH 3.3-4.0. It is freely soluble ( $\geq 10.0$  mg/mL) in methanol (gels), ethanol (gels), and water at pH of 2.2 (gels), 2.4-3.1, 4.3-4.5, 4.6-5.6.

## 12 CLINICAL TRIALS

### 12.1 Trial Design and Study Demographics

#### **ACUITY (UA/NSTEMI)**

The ACUITY trial was carried out in 13,819 patients with moderate or high risk acute coronary syndromes due to unstable angina or non-ST-segment elevation myocardial infarction who were undergoing an early invasive strategy using a PROBE design (Prospective Randomized Open-label Blinded Endpoint) to determine the non-inferiority and/or superiority of bivalirudin with or without glycoprotein IIb/IIIa inhibitors (GPI) to heparin or enoxaparin with GPI. Additional anti-platelet therapy utilised in the study included acetylsalicylic acid (ASA) and clopidogrel.

Patients were equally randomized to treatment in one of three arms: bivalirudin alone, bivalirudin plus planned use of GPI (abciximab, eptifibatide, or tirofiban), or heparin (either UFH or enoxaparin) plus planned use of GPI. Rescue GPIs were used during PCI for procedural complications in 6.6% of patients who were randomized to bivalirudin alone due to any of the following circumstances:

1. new or persistent thrombus formation during or after PCI;
2. slow or no reflow;
3. distal embolization;
4. side branch closure;
5. other reasons for which the operator feels patient safety requires a GPI.

There were no significant differences in baseline characteristics between the three treatment groups. Patients ranged in age from 20-95 years (median 63 years); 45% were  $\geq 65$  years; weight ranged from 34-195 kg (median 83 kg); 30.1% were female; 59% had abnormal cardiac markers (Creatine Kinase –MB [CK-MB], troponin T or I); and 38% had ST segment deviations. In the bivalirudin arm, 2,078 patients had received prior heparin (UFH, LMWH) prior to being randomized to receive bivalirudin. Angiography was performed in 99% of the patients. Patients were subsequently triaged to either PCI (56%), CABG (11%) or medical management (33%). Stents were deployed in 85% of patients who underwent PCI (drug-eluting stents in 60%). Ninety-six percent of patients received ASA.

Bivalirudin was administered as a 0.1 mg/kg bolus followed by an infusion of 0.25 mg/kg/h. For the patients who underwent PCI, an additional bolus of 0.50 mg/kg was administered and the infusion rate increased to 1.75 mg/kg/h for the duration of the procedure. At investigator discretion, the infusion was continued following the procedure at a dose of 0.25 mg/kg/h. For patients being medically managed or planned for CABG, a dose of 0.25 mg/kg/h was continued at physician discretion. Heparin was administered as a 60 U/kg bolus followed by a 12 U/kg/h infusion through angiography; dosing was adjusted appropriately for PCI and CABG. Enoxaparin and GPIs were administered according to manufacturers' instructions.

#### **HORIZONS (STEMI undergoing primary PCI)**

The HORIZONS trial was a prospective, dual arm, single blind, randomised, multi-centre trial to establish the safety and efficacy of bivalirudin in patients with STEMI undergoing a primary PCI strategy with stent implantation with either a slow release paclitaxal-eluting stent (TAXUS™) or an otherwise identical uncoated bare metal stent (Express2™). A total of 3,602 patients were randomised to receive either bivalirudin (1,800 patients) or unfractionated heparin plus a GP IIb/IIIa inhibitor (1,802 patients). All patients received ASA and clopidogrel, with twice as many patients (approximately 64%) receiving a 600 mg loading dose of clopidogrel than a 300 mg

loading dose of clopidogrel. Approximately 66% of patients were pre-treated with unfractionated heparin.

The dose of bivalirudin used in HORIZONS was the same as that used in the REPLACE-2 study (0.75 mg/kg bolus followed by 1.75 mg/kg/h infusion). A total of 92.9% of patients treated underwent primary PCI as their primary management strategy.

### **REPLACE-2 (Randomized Evaluation of PCI Linking Bivalirudin Reduced Clinical Events)**

Bivalirudin has been evaluated in five interventional cardiology trials reporting 19,211 patients. Stents were deployed over 13,224 of the patients in these trials - mainly in trials performed since 1995. PTCA, atherectomy or other procedures were performed in the remaining patients.

Bivalirudin plus provisional platelet GPIIb/IIIa inhibition was evaluated versus heparin plus planned GPIIb/IIIa inhibition in 6010 patients undergoing PCI in the double-blind, randomized, multi-centre REPLACE-2 trial (Randomized Evaluation in PCI linking bivalirudin to reduced Clinical Events).

Patients were aged 25-95 years with body weights 35-199 kg. Indications for PCI included unstable angina (35% of patients), myocardial infarction (MI) within 7-days prior to intervention (8%), stable angina (25%) and positive ischemic stress test (24%). Stents were deployed in 85% of patients, balloon angioplasty, atherectomy and other procedures were performed in 15%. Pretreatment with ASA (given in 99%) and thienopyridines (86%) was based on protocol recommendations. Pretreatment with other anticoagulants was allowed by protocol.

Bivalirudin was administered as a 0.75 mg/kg bolus followed by a 1.75 mg/kg/h infusion for the duration of the procedure. At investigator discretion, the infusion could be continued following the procedure for up to 4 hours. The median infusion duration was 44 minutes. Heparin was administered as a 65 U/kg bolus. Abciximab and eptifibatide were given according to manufacturers' instructions. Both randomised groups could be given "provisional" treatments with GPIIb/IIIa inhibitors during the PCI at investigator discretion, but under double-blind conditions. Provisional treatment with GPIIb/IIIa inhibitors was requested in 5.2% of patients randomised to heparin plus GPIIb/IIIa (they were given placebo) and in 7.2% patients randomised to bivalirudin (they were given abciximab or eptifibatide according to pre-randomisation investigator choice and patient stratification). Reasons for provisional treatment included new or suspected thrombus, dissection with decreased flow and decreased Thrombolysis In Myocardial Infarction (TIMI) flow (0-2) or slow reflow.

The ACT (measured by a Hemochron® device) was checked 5 minutes after the first bolus of study medication. For patients randomised to bivalirudin, the median 5-minute ACT was 358 seconds (interquartile range 320-400 seconds) and the ACT was <225 seconds in 3%. For patients randomised to heparin plus GPIIb/IIIa inhibitors, the median 5-minute ACT was 317 seconds (interquartile range 263-373 seconds) and the ACT was <225 seconds in 12%. At the end of the procedure, median ACT values were 344 seconds (bivalirudin group) and 276 seconds (heparin plus GPIIb/IIIa inhibitor group).

Bivalirudin was also evaluated in patients with unstable angina undergoing PTCA in two randomised, double-blind, multicenter studies with identical protocols (the BAT trial, Bivalirudin Angioplasty Trial). Overall, 4,312 patients with unstable angina, including 741 patients (17%) with post-MI angina, were treated in a 1:1 randomised fashion with bivalirudin or heparin. Patients evaluated had a median age of 63 years (range 29-90 years) and a median weight of

80 kg (range 39-120 kg), with 68% male, and 91% Caucasian. Twenty-three percent of patients were treated with open-label heparin within one hour prior to randomisation. All patients were administered ASA 300-325 mg prior to PTCA, and daily thereafter.

Patients randomised to bivalirudin were started on an IV infusion of bivalirudin of 2.5 mg/kg/h in a double-blind fashion. Within 5 minutes after starting the infusion, and prior to PTCA, a 1 mg/kg loading dose was administered as an IV bolus. The infusion was continued for 4 hours, then the infusion was changed, under double-blind conditions, to bivalirudin at 0.2 mg/kg/h for up to an additional 20 hours, with patients receiving this infusion for an average of 14 hours. The ACT was checked at 5 minutes and at 45 minutes following commencement of the bivalirudin infusion. If on either occasion the ACT was < 350 seconds, an additional double-blinded bolus of placebo was administered. The bivalirudin dose was not titrated to ACT. Median ACT values (and observed values between the 5th and 95th percentile) were: 345 seconds (240-595 seconds) at 5 minutes, and 346 seconds (269-583 seconds) at 45 minutes after initiation of dosing.

Patients randomised to heparin were given a loading dose of 175 IU/kg in a double-blind fashion as an IV bolus 5 minutes before the planned procedure, after commencement of an initial infusion of heparin at 15 IU/kg/h. The infusion was continued for 4 hours. After 4 hours, the heparin infusion was changed, under double-blind conditions, to remain at heparin 15 IU/kg/h for up to 20 additional hours. The ACT was checked at 5 minutes and at 45 minutes following commencement of the infusion. If on either occasion the ACT was < 350 seconds, an additional double-blind bolus of heparin at 60 IU/kg was administered. Once the target ACT was achieved for heparin patients, no further ACT measurements were performed. The protocol allowed use of open-label heparin at the discretion of the investigator after discontinuation of blinded study medication, whether or not an endpoint event, pre-defined as “procedural failure”, had occurred. The use of open-label heparin after administration of test drug was similar between bivalirudin and heparin treatment groups, at about 20% in both groups.

**CHOOSE (CABG/HIT/TS On- and Off-pump Safety and Efficacy) and EVOLUTION (Evaluation of patients during coronary artery bypass graft Operation: Linking Utilization of Bivalirudin To Improved Outcomes and New anticoagulant strategy)**

The results of four trials provided clinical substantiation that bivalirudin is a safe and effective anticoagulant for use in patients with or at risk of HIT/TS undergoing cardiac surgery. Each of the two CHOOSE efficacy studies in patients with or at risk of HIT/TS undergoing on- or off-pump cardiac surgery included 50 prospective patients administered bivalirudin compared to approximately 50 historical control patients. Patients were considered to be with or at risk of HIT/TS if they had a new diagnosis or a documented history of HIT/TS. This was defined by a positive platelet aggregation assay, functional assay, or immunoassay for HPF-4 antibodies, and/or thrombocytopenia (platelet count decreased 50% or more from baseline) associated with heparin use. In addition patients with HIT plus any evidence of arterial or venous thrombosis (HITTS) were eligible for inclusion. The two EVOLUTION safety studies were each conducted in 150 non-HIT/TS patients undergoing on- or off-pump cardiac surgery, randomized 2:1, bivalirudin to heparin/protamine.

Patients in the CHOOSE and EVOLUTION studies had a median age ranging from 64-67 years, 69-74% were male and 87-93% were Caucasian in the two treatment groups. The median weight ranged from 77-88 kg with a corresponding Body Mass Index (BMI) of 27-29.

In the on-pump studies, patients were dosed with a bivalirudin IV bolus of 1.0 mg/kg followed by an IV infusion of 2.5 mg/kg/h; patients undergoing off-pump surgery were dosed with an IV bolus of 0.75 mg/kg followed by an IV infusion of 1.75 mg/kg/h.

## 12.2 Study Results

### **ACUITY (UA/NSTEMI)**

The primary analysis and results for ACUITY at 30-days and 1 year for the overall (ITT) population and for the patients that received ASA and clopidogrel as per protocol (pre-angiography or pre-PCI) are shown in **Table 15** and **Table 16**.

**Table 15: ACUITY trial; 30-day and 1-year risk differences for the composite ischaemic endpoint and its components for the overall population (ITT)**

	Overall population (ITT)				
	Arm A UFH/enox +GPI (N=4,603) %*	Arm B bival +GPI (N=4,604) %*	B – A Risk diff. (95% CI)	Arm C bival alone (N=4,612) %*	C – A Risk diff. (95% CI)
<b>30-day</b>					
<b>Composite ischemia</b>	7.3	7.7	0.48 (-0.60, 1.55)	7.8	0.55 (-0.53, 1.63)
<b>Death</b>	1.3	1.5	0.17 (-0.31, 0.66)	1.6	0.26 (-0.23, 0.75)
<b>MI</b>	4.9	5.0	0.04 (-0.84, 0.93)	5.4	0.45 (-0.46, 1.35)
<b>Unplanned revasc.</b>	2.3	2.7	0.39 (-0.24, 1.03)	2.4	0.10 (-0.51, 0.72)
<b>1-year</b>					
<b>Composite ischemia</b>	15.3	15.9	0.65 (-0.83, 2.13)	16.0	0.71 (-0.77, 2.19)
<b>Death</b>	3.9	3.8	0.04 (-0.83, 0.74)	3.7	-0.18 (-0.96, 0.60)
<b>MI</b>	6.8	7.0	0.19 (-0.84, 1.23)	7.6	0.83 (-0.22, 1.89)
<b>Unplanned revasc.</b>	8.1	8.8	0.78 (-0.36, 1.92)	8.4	0.37 (-0.75, 1.50)

UFH=unfractionated heparin; enox=enoxaparin; bival=bivalirudin; GPI=glycoprotein IIb/IIIa inhibitor; revasc=revascularization

\* % represents the incidence of observed events

**Table 16: ACUITY trial; 30-day and 1-year risk differences for the composite ischemic endpoint and its components for patients that received ASA and clopidogrel as per protocol\*\***

	Patients receiving ASA & clopidogrel as per protocol**				
	Arm A UFH/enoxaparin + GPI (N=2,842) %*	Arm B Bivalirudin + GPI (N=2,924) %*	B – A Risk difference (95% CI)	Arm C Bivalirudin alone (N=2,911) %*	C – A Risk diff. (95% CI)
<b>30-day</b>					
<b>Composite ischemia</b>	7.4	7.4	0.03 (-1.32, 1.38)	7.0	-0.35 (-1.68, 0.99)
<b>Death</b>	1.4	1.4	-0.00 (-0.60, 0.60)	1.2	-0.14 (-0.72, 0.45)
<b>MI</b>	4.8	4.9	0.04 (-1.07, 1.14)	4.7	-0.08 (-1.18, 1.02)
<b>Unplanned revasc.</b>	2.6	2.8	0.23 (-0.61, 1.08)	2.2	-0.41 (-1.20, 0.39)
<b>1-year</b>					
<b>Composite ischemia</b>	16.1	16.8	0.68 (-1.24, 2.59)	15.8	-0.35 (-2.24, 1.54)
<b>Death</b>	3.7	3.9	0.20 (-0.78, 1.19)	3.3	-0.36 (-1.31, 0.59)
<b>MI</b>	6.7	7.3	0.60 (-0.71, 1.91)	6.8	0.19 (-1.11, 1.48)
<b>Unplanned revasc.</b>	9.4	10.0	0.59 (-0.94, 2.12)	8.9	-0.53 (-2.02, 0.96)

UFH=unfractionated heparin; GPI=glycoprotein IIb/IIIa inhibitor; revasc.=revascularization

\* % represents the incidence of observed events

\*\*clopidogrel pre-angiography or pre-PCI

ACUITY major bleeding was defined as any one of the following: intracranial, retroperitoneal, intraocular, access site hemorrhage requiring radiological or surgical intervention,  $\geq 5$  cm diameter hematoma at puncture site, reduction in hemoglobin concentration of  $\geq 4$  g/dl without an overt source of bleeding, reduction in hemoglobin concentration of  $\geq 3$  g/dl with an overt source of bleeding, re-operation for bleeding or use of any blood product transfusion. Minor bleeding was defined as any observed bleeding event that did not meet the criteria as major.

Major bleeding rates are shown in **Table 17** for the IIT population (patients receiving clopidogrel and acetylsalicylic acid). Both major and minor bleeds were significantly less frequent with bivalirudin alone than the heparin plus GP IIb/IIIa inhibitor and bivalirudin plus GP IIb/IIIa inhibitor groups. Similar reductions in bleeding were observed in patients who were switched to bivalirudin from heparin-based therapies (N = 2,078).

The incidence of both ACUITY-scale and TIMI-scale bleeding events to day 30 for the per protocol population are presented in **Table 18**.

The advantage of bivalirudin over UFH/enoxaparin plus GP IIb/IIIa inhibitor in terms of bleeding events was only observed in the bivalirudin monotherapy arm.

**Table 17: ACUITY trial: Major bleeding rates at 30 days for intent-to-treat population**

	Bivalirudin (%) N = 4,612	Bivalirudin + GPI (%) N = 4,604	UFH/Enox + GPI(%) N = 4,603
Protocol defined major bleeding	3.0	5.3	5.7
TIMI Major (non-CABG) Bleeding	0.9	1.8	1.9

UFH=unfractionated heparin; enox=enoxaparin; GPI=glycoprotein IIb/IIIa inhibitor  
\* % represents the incidence of observed events

**Table 18: ACUITY trial; bleeding events up to day 30 for the population of patients who received acetylsalicylic acid and clopidogrel as per protocol\*\***

	UFH/Enoxaparin + GPI (%)* N=2,842	Bivalirudin + GPI(%)* N = 2,924*	Bivalirudin alone (%) N = 2,911
ACUITY scale major bleeding	5.9	5.4	3.1
TIMI scale major bleeding	1.9	1.9	0.8

UFH=unfractionated heparin; GPI=glycoprotein IIb/IIIa inhibitor  
\* % represents the incidence of observed events  
\*\*clopidogrel pre-angiography or pre-PCI

### **HORIZONS (STEMI undergoing primary PCI)**

In the HORIZONS study, the key efficacy endpoint of MACE (Major Adverse Ischaemic Cardiac Events) included any death, reinfarction, ischaemic TVR, or stroke. The primary analysis and results for HORIZONS at 30 days and 1 year for the overall (ITT) population are shown in **Table 19**. Results at 1 year were consistent with results at 30 days.

**Table 19: HORIZONS trial: 30-day and 1-year results for the composite endpoint (MACE) and its components for the overall population (ITT)**

	Overall population (ITT)				
	n/N (%) of Patients		Estimate [95% CI]		
	Bivalirudin	UFH + GP IIb/IIIa	Difference	Relative Risk	P-value <sup>a</sup>
30-day					
MACE	98/1,800 (5.4)	100/1,802 (5.5)	-0.1 [-1.6, 1.4]	0.98 [0.75, 1.29]	0.8901
Death	37/1,800 (2.1)	56/1,802 (3.1)	-1.1 [-2.1, 0.0]	0.66 [0.44, 1.00]	0.0465
Reinfarction	34/1,800 (1.9)	32/1,802 (1.8)	0.1 [-0.8, 1.0]	1.06 [0.66, 1.72]	0.8003
Ischemic TVR	45/1,800 (2.5)	35/1,802 (1.9)	0.6 [-0.5, 1.6]	1.29 [0.83, 1.99]	0.2561
Stroke	14/1,800 (0.8)	12/1,802 (0.7)	0.1 [-0.5, 0.7]	1.17 [0.54, 2.52]	0.6917

Overall population (ITT)					
	n/N (%) of Patients		Estimate [95% CI]		
	Bivalirudin	UFH + GP IIb/IIIa	Difference	Relative Risk	P-value <sup>a</sup>
1-year					
MACE	209/1,800 (11.6)	210/1,802 (11.7)	-0.0 [2.2, 2.1]	1.00 [0.83, 1.19]	0.9682
Death	61/1,800 (3.4)	86/1,802 (4.8)	-1.4 [-2.7, 0.0]	0.71 [0.51, 0.98]	0.0359
Reinfarction	62/1,800 (3.4)	76/1,802 (4.2)	-0.8 [-2.1, 0.5]	0.82 [0.59, 1.13]	0.2268
Ischemic TVR	123/1,800 (6.8)	100/1,802 (5.5)	1.3 [-0.3, 2.9]	1.23 [0.95, 1.59]	0.1099
Stroke	20/1,800 (1.1)	20/1,802 (1.1)	0.0 [-0.7, 0.7]	1.00 [0.54, 1.85]	0.9972

<sup>a</sup> Superiority p-value.

### **REPLACE-2 (Randomized Evaluation of PCI Linking Bivalirudin Reduced Clinical Events)**

In the REPLACE-2 trial, the primary protocol endpoint was a composite of three efficacy variables measured 30 days post-procedure, (death, MI, and urgent revascularization), and one safety variable, (in-hospital major hemorrhage), adjudicated under double-blind conditions. The rates of this composite endpoint were similar in the bivalirudin and heparin plus GPIIb/IIIa inhibitor treatment groups. The secondary composite ischemic endpoint of death, MI or urgent revascularisation was reported with similar incidence in both groups. Major hemorrhage was reported significantly less frequently in patients randomised to bivalirudin. Study outcomes are shown in **Table 20**.

**Table 20: Incidences of clinical endpoints at 30 days for REPLACE-2 in patients undergoing PCI**

	Intention-to-treat population			Per-protocol population		
	Bivalirudin (N=2,994) [%]	Heparin + GPIIb/IIIa inhibitor (N=3,008) [%]	O.R (95% C.I.)	Bivalirudin (N=2,902) [%]	Heparin + GPIIb/IIIa inhibitor (N=2,882) [%]	O.R. (95% C.I.)
Primary (quadruple) endpoint	9.2	10.0	0.92 (0.77-1.09)	9.2	10.0	0.91 (0.77-1.09)
Secondary (triple) endpoint	7.6	7.1	1.09 (0.90-1.32)	7.8	7.1	1.10 (0.90-1.34)
Endpoint components						
Death	0.2	0.4	0.59 (0.23-1.49)	0.2	0.4	0.5 (0.19-1.32)
Myocardial Infarction	7.0	6.2	1.13 (0.92-1.39)	7.1	6.4	1.12 (0.91-1.37)
Urgent revascularization	1.2	1.4	0.84 (0.53-1.31)	1.2	1.3	0.91 (0.57-1.46)
Major bleeding	2.4 <sup>#</sup>	4.1	0.57 (0.42-0.77)	2.2	4.0	0.56 (0.41-0.76)

<sup>#</sup> p<0.001 vs. heparin + GPIIb/IIIa inhibitor  
C.I. = Confidence interval; O.R. = Odds ratio

## **BAT (Bivalirudin Angioplasty Trial)**

In the BAT trial, the studies were designed to demonstrate the safety and efficacy of bivalirudin in patients undergoing PTCA as a treatment for unstable angina. The primary pre-specified endpoint was a composite endpoint called “procedural failure”, which included both clinical and angiographic elements measured during hospitalisation. The clinical elements were the occurrence of death, MI, or urgent revascularisation, while the angiographic elements were identified as impending or abrupt vessel closure. The pre-specified safety endpoint was major hemorrhage.

The median duration of hospitalisation was 4 days for both the bivalirudin and heparin treatment groups. The rates of so-called procedural failure were similar in the bivalirudin and heparin treatment groups. Study outcomes are shown in **Table 21** below for the intent-to-treat population.

**Table 21: Incidence of in-hospital clinical endpoints in BAT trial occurring within 7 days**

<b>All Patients</b>	<b>Bivalirudin n = 2,161</b>	<b>Heparin n = 2,151</b>	<b>P Value</b>
<b>Efficacy Endpoints:</b>			
Procedural Failure <sup>1</sup>	7.9%	9.3%	0.108
Death, MI, Revascularisation	6.2%	7.9%	0.039
Death	0.2%	0.2%	0.987
MI <sup>2</sup>	3.3%	4.2%	0.126
Revascularisation <sup>3</sup>	4.2%	5.6%	0.030
<b>Safety Endpoint:</b>			
Major Hemorrhage <sup>4</sup>	3.5%	9.3%	< 0.001

1. The protocol specified primary endpoint (a composite of death or MI or clinical deterioration of cardiac origin requiring revascularisation or placement of an aortic balloon pump or angiographic evidence of abrupt vessel closure).
2. Defined as: Q-wave MI; CK-MB elevation  $\geq 2 \times \text{ULN}$ , new ST- or T-wave abnormality, and chest pain  $\geq 30$  min; OR new LBBB with chest pain  $\geq 30$  min and/or elevated CK-MB enzymes; OR elevated CK-MB and new ST- or T-wave abnormality without chest pain; OR elevated CK-MB.
3. Defined as: any revascularisation procedure, including angioplasty, CABG, stenting, or placement of an intra-aortic balloon pump.
4. Defined as the occurrence of any of the following: intracranial bleeding, retroperitoneal bleeding, clinically overt bleeding with a decrease in hemoglobin  $\geq 3$  g/dL or leading to a transfusion of 2 units of blood.

In evaluating the efficacy and safety of bivalirudin in these clinical studies, the relatively high initial bolus dose of heparin (175 IU/kg) used in the comparator group should be noted. This is reflected by the mean ACT values reported in these studies of 377 seconds for bivalirudin-treated patients at 5 minutes after initiation of therapy, compared to 414 seconds with heparin; and 380 seconds for bivalirudin-treated patients at 45 minutes after initiation, compared to 418 seconds in those treated with heparin. Mean baseline ACT values were virtually identical for both groups at 145 and 144 seconds, respectively.

## **CHOOSE (CABG/HIT/TS On- and Off-pump Safety and Efficacy) and EVOLUTION (Evaluation of patients during coronary artery bypass graft Operation: Linking Utilization of Bivalirudin To Improved Outcomes and New anticoagulant strategy)**

In the CHOOSE and EVOLUTION trials, the primary endpoint was procedural success, defined as the absence of death, Q-wave MI, repeat coronary revascularization, and stroke at Day 7 or discharge, whichever occurred first. Procedural success rates were similar in the bivalirudin and

the comparator groups in the CHOOSE and EVOLUTION studies at Day 7/discharge and at Day 30 (see **Table 22**). The incidences of death, Q-wave MI, revascularization and stroke were few and were similar in the treatment groups. The clinical trial data indicated that any of the commonly used activated clotting tests may be used to ensure that the patient is adequately anticoagulated following administration of bivalirudin.

**Table 22: Procedural success for the CHOOSE (patients with or at risk of HIT/TS) and EVOLUTION (non-HIT/TS patients) studies in cardiac surgery (ITT Population)**

Parameter	CHOOSE Studies (HIT/TS) <sup>1</sup>				EVOLUTION Studies (Non-HIT/TS) <sup>2</sup>			
	On-pump		Off-pump		On-pump		Off-pump	
	Bivalirudin n/N (%)	Historical Control n/N (%)	Bivalirudin n/N (%)	Historical Control n/N (%)	Bivalirudin n/N (%)	Heparin/ Protamine n/N (%)	Bivalirudin n/N (%)	Heparin/ Protamine n/N (%)
<b>Procedural success<sup>3</sup>:</b>								
<b>Day 7/ discharge</b>	46/50 (92.0)	69/75 (92.0)	50/52 (96.2)	35/36 (97.2)	96/101 (95.0)	47/49 (95.9)	101/105 (96.2)	49/52 (94.2)
<b>Day 30</b>	45/50 (90.0)	68/75 (90.7)	48/51 (94.1)	32/36 (88.9)	95/101 (94.1)	47/49 (95.9)	97/104 (93.3)	48/52 (92.3)

<sup>1</sup> Investigator-reported Q-wave MI data were used for the CHOOSE studies because data from the historical cohort could not be adjudicated

<sup>2</sup> Q-wave MI data adjudicated by an independent Clinical Events Committee are used for these studies

<sup>3</sup> Defined as absence of death, Q-wave MI, stroke and revascularization

### 13 NON-CLINICAL TOXICOLOGY

Bivalirudin was administered to animals for up to 28 days by continuous IV infusion at dose levels of up to 80 times the clinically recommended dose of 15 mg/kg/day. Toxicological effects observed were directly related to the route of administration and to the anticoagulant activity of bivalirudin, such as local injection site phlebitis and hemorrhage, and internal organ hemorrhage. Bivalirudin caused no signs of toxicity at clinically relevant doses administered by either repeated IV injection or continuous infusion for up to 28 days.

The relative anticoagulant activity of various species is reported below in **Table 23**.

**Table 23: Estimates in Several Species of Bivalirudin Concentration Required to Prolong aPTT to 3 Times Baseline**

Species	Effective Conc. (mcg/mL)*	Relative to Human
Human	0.82	1
Baboon	0.35	0.4
Monkey	0.9	1.1
Rat	1.8	2.3
Dog	3.5	4.3
Rabbit	14	17.1
Pig	24	29.3

\*Required to prolong aPTT to 3 times baseline.

### **Acute Toxicity:**

*Mouse:* No overt toxicity was observed within a 14-day observation period at IV and subcutaneous (s.c.) doses up to and including 200 mg/kg.

*Rat:* An acute single dose IV study in rats assessed doses up to 200 mg/kg, when administered in 10 mL/kg saline infusion, and included a 14-day observation period. This study showed enlargement of the thymus gland and submandibular lymph nodes in both sexes. Acute toxicity was also observed, including death, respiratory distress, piloerection and vascular congestion of the lungs. Findings were observed at all dose levels.

Another study, examining a 100 mg/kg single IV dose, administered in 2 mL/kg saline infusion, with a 14-day follow-up observation period, reported no adverse effects.

*Monkey:* No mortality or adverse effects attributable to bivalirudin were observed in two monkeys administered doses up to 42 mg/kg over a four hour period by IV infusion.

### **Subchronic and Chronic Toxicity:**

*Rat:* Continuous IV infusion for 7 to 28 days at doses from 25 to 1200 mg/kg/day caused no adverse effects at 25 mg/kg/day. Mortality was observed at doses of 250 mg/kg/day for 28 days (2 of 30 animals) and 500 mg/kg/day for 28 days (2 of 10 animals) and above. At 500, 1000, and 1200 mg/kg/day, in addition to mortality, hemorrhage of internal organs was observed. A dose of 75 mg/kg/day and above for 28 days produced phlebitis at the injection site accompanied by effects in the spleen (enlargement), liver (sinusoidal histiocytosis/necrosis), and bone marrow (myeloid hypercellularity).

A study has also been done to assess the toxicity and toxicokinetic profile of a liquid formulation of bivalirudin (BIVALIRUDIN INJECTION), compared to a lyophilized formulation of bivalirudin when administered continuously via intravenous infusion to rats for 14 days.

There were no bivalirudin-related effects on clinical signs, body weight, food consumption, ophthalmology, hematology, coagulation, urinalysis or organ weights for both formulations. Minor, non-adverse clinical chemistry changes occurred at ~258 mg/kg/day with both products.

Rats given ~258 mg/kg/day via continuous intravenous infusion for 14 days had mortality related directly or indirectly to hemorrhage. Findings included dark material in the gastrointestinal tract, pallor of the skin and organs, centrilobular necrosis in the liver and hemoglobin crystals in the lungs. Hemorrhage was also observed in the ovary in a ~258 mg/kg/day female given BIVALIRUDIN INJECTION that survived to study termination. Hemorrhage was consistent with the mode of action of the test article (direct acting thrombin inhibitor), so these findings were considered to be product related. Rats administered with the liquid formulation and rats administered the lyophilized formulation were similarly affected. These findings were not observed in rats given 36 or 100mg/kg/day of BIVALIRUDIN INJECTION.

Under the conditions of the study, the NOAEL of BIVALIRUDIN INJECTION was considered to be 100 mg/kg/day, due to the unscheduled deaths/sacrifices at ~258 mg/kg/day of bivalirudin. The NOAEL corresponds with a  $C_{max}$  of  $2500 \pm 200$  ng/ml in males and  $1800 \pm 300$  ng/mL in females. Overall, there were no differences noted between rats administered with BIVALIRUDIN INJECTION and rats administered the lyophilized formulation.

*Monkey:* Clinical signs, body weight, and food consumption appeared normal in cynomolgus monkeys following continuous IV infusion for 14 or 28 days at doses of 15 and 45 mg/kg/day.

Internal organ hemorrhage was identified in some animals receiving 150 mg/kg/day over 14 days. Anticoagulant activities maintained during the study were approximately 85, 200, and 350 percent above baseline levels at the three doses tested, respectively. In a 28-day study, myocardial degeneration and/or necrosis were noted in 2 monkeys receiving the highest dose of 150 mg/kg/day. The lesions were associated with mild hemorrhage and appeared to occur during the last 7 to 10 days of the 28-day treatment period. No cardiac lesions were evident in monkeys treated with bivalirudin at 150 mg/kg/day for 14 days.

### **Special Studies:**

Bivalirudin, when administered subcutaneously once/week at 1 mg/kg for 3 weeks was considered non-antigenic in guinea pigs.

No antibodies cross-reacting with bivalirudin were detected in monkeys receiving IV doses up to 100 mg/kg and up to 150 mg/kg/day for 14 days by continuous infusion.

Bivalirudin at 10 mg/mL did not cause hemolysis or plasma protein flocculation of human blood *in vitro*.

### **Carcinogenesis and Genotoxicity:**

No long-term studies in animals have been performed to evaluate the carcinogenic potential of bivalirudin. Bivalirudin displayed no genotoxic potential in the *in vitro* bacterial cell reverse mutation assay (Ames test), the *in vitro* Chinese hamster ovary cell forward gene mutation test (CHO/HGPRT), the *in vitro* human lymphocyte chromosomal aberration assay, the *in vitro* rat hepatocyte unscheduled DNA synthesis (UDS) assay, and the *in vivo* rat micronucleus assay.

### **Reproductive and Developmental Toxicity:**

*Rat:* Reproductive toxicity, as defined by adverse effects on mating and fertility indices, was observed only at dose levels associated with toxicity, i.e. 150 and 500 mg/kg/day.

Developmental toxicity, i.e. adverse fetal effects, was observed only at maternally toxic doses of 150 and 500 mg/kg/day.

No teratogenic effects were evident at any doses evaluated.

*Rabbit:* Neither maternal nor developmental adverse effects were observed up to and including bivalirudin doses of 150 mg/kg/day.

## **14 SUPPORTING PRODUCT MONOGRAPHS**

Angiomax® (250 mg/vial), submission control 197740, Product Monograph, Sandoz Canada Inc. (Sep. 28, 2016)

## READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

### PATIENT MEDICATION INFORMATION

#### Pr BIVALIRUDIN INJECTION

Read this carefully before you start taking BIVALIRUDIN INJECTION and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about BIVALIRUDIN INJECTION.

#### **What is BIVALIRUDIN INJECTION used for?**

**BIVALIRUDIN INJECTION** is an anticoagulant drug that is used to prevent blood from clotting. It is used in adults to treat:

- patients with ST-segment elevation myocardial infarction [STEMI (a severe type of heart attack)] undergoing Percutaneous Coronary Intervention (PCI), (a procedure that unblocks narrowed coronary arteries without having to perform surgery)
- patients with moderate- to high-risk acute coronary syndromes (ACS) due to unstable angina or non-ST segment elevation myocardial infarction (a type of heart attack) undergoing PCI, or who will be managed with medicines only, or who will have cardiac (heart) surgery called a Coronary Artery Bypass Graft (CABG) (sometimes referred to as “bypass” surgery)

BIVALIRUDIN INJECTION is intended for use with ASA (aspirin). It can also be used instead of a drug called heparin if you are at risk of having low blood cell counts due to heparin.

#### **How does BIVALIRUDIN INJECTION work?**

BIVALIRUDIN INJECTION is a direct thrombin-inhibitor that prevents blood from clotting during and after PCI or heart surgery.

#### **What are the ingredients in BIVALIRUDIN INJECTION?**

Medicinal ingredients: Bivalirudin

Non-medicinal ingredients: Glacial acetic acid, Polyethylene glycol, Sodium acetate trihydrate, Sodium hydroxide and Water for injection.

#### **BIVALIRUDIN INJECTION comes in the following dosage forms:**

A ready-to-use solution for intravenous (IV) injection. Each 50 mL vial contains 250 mg (5 mg / mL) of bivalirudin.

#### **Do not use BIVALIRUDIN INJECTION if:**

- you are allergic to bivalirudin or to any ingredient of BIVALIRUDIN INJECTION (see ‘What are the ingredients in BIVALIRUDIN INJECTION’ above)
- you have uncontrollable active bleeding
- you have a major blood clotting disorder

- you have acute stomach or intestinal ulcer
- you have bleeding in the brain
- you have severe trauma to the brain or spine
- you have a bacterial infection in your heart valves or inner layer of the heart wall (bacterial endocarditis)
- you have severe uncontrolled high blood pressure
- you have an eye problem called “retinopathy” caused by diabetes or bleeding
- you are using spinal/epidural anesthesia

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take BIVALIRUDIN INJECTION. Talk about any health conditions or problems you may have, including if you:**

- are at risk of bleeding.
- are pregnant, planning on becoming pregnant or are breastfeeding. BIVALIRUDIN INJECTION should not be used during pregnancy, unless clearly necessary. Your doctor will decide whether or not this treatment is appropriate for you.
- are taking blood thinners or medicines to prevent blood clots (anticoagulants e.g., warfarin, dabigatran, apixaban, rivaroxaban, ASA, clopidogrel, prasugrel, ticagrelor).

**Other warnings you should know about:**

**Risk of Bleeding:**

As with any drug that prevents blood from clotting, you may be at risk for bleeding during or after your PCI or heart surgery. You may be at an increased risk for bleeding if you are elderly, female or being given other drugs known to cause bleeding like heparin or warfarin. This bleeding could occur anywhere inside the body [e.g., stomach, digestive system (including vomiting blood or passing blood with the stools), abdomen, lungs, groin, bladder, heart, eye, ear, nose, or brain]. This may rarely result in a stroke or be fatal.

Signs of bleeding include:

- Nose or gum bleeds
- Blood in urine or stool
- Bruising easily
- A rash of red, round spots under the skin
- Swelling or pain in the groin or the arm
- Back pain
- Headache
- Coughing blood
- Sweating
- Feeling faint or sick or dizzy due to low blood pressure.

Talk to your doctor immediately if you are concerned about your risk for bleeding or have any of these signs of bleeding after your PCI or heart surgery.

**Blood Transfusions:**

In patients undergoing heart surgery, it is often necessary to receive a blood transfusion. In patients undergoing PCI, the need for transfusions is less common.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

**The following may interact with BIVALIRUDIN INJECTION:**

- Drugs that break up blood clots such as heparin or warfarin
- Drugs that prevent platelets from binding together such as glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors such as Aggrastat® and Integrilin®

Using these drugs at the same time as BIVALIRUDIN INJECTION could lead to an increase in bleeding.

**How to take BIVALIRUDIN INJECTION:**

BIVALIRUDIN INJECTION is only administered by trained medical professionals through an intravenous line.

**Usual dose:**

The dose of BIVALIRUDIN INJECTION you will receive will be based on your weight and will depend on if you are having PCI or heart surgery. Your dose may be reduced if you have severe kidney problems.

**Overdose:**

If you think you have been given too much BIVALIRUDIN INJECTION, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

**What are possible side effects from using BIVALIRUDIN INJECTION?**

These are not all the possible side effects you may feel when taking BIVALIRUDIN INJECTION. If you experience any side effects not listed here, contact your healthcare professional.

- Anxiety
- Constipation
- Indigestion
- Nausea
- Nervousness
- Trouble sleeping
- Vomiting

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<b>COMMON</b>			
<b>Anemia</b> (decreased number of red blood cells): fatigue, loss of energy, irregular heartbeats, pale complexion, shortness of breath, weakness		✓	
<b>Hypotension</b> (low blood pressure): dizziness, fainting, light-headedness, blurred vision, nausea, vomiting, fatigue (may occur when you go from lying or sitting to standing up)		✓	
Difficulty urinating or decreased urine volume		✓	
Fever (with or without cough and/or difficulty breathing)		✓	
Headache		✓	
Heart attack		✓	
<b>Arrhythmia</b> (abnormal heart rhythms): rapid, slow or irregular heartbeat		✓	
<b>Hypertension</b> (high blood pressure): shortness of breath, fatigue, dizziness or fainting, chest pain or pressure, swelling in your ankles and legs, bluish colour to your lips and skin, racing pulse or heart palpitations		✓	
Pain (including back, pelvic/abdominal, or chest pain)		✓	
Swelling of the hands and/or feet		✓	
<b>Hemorrhage</b> (major bleeding): at any site including at the puncture site, from the nose, in the stomach, in the respiratory tract		✓	
<b>Atelectasis</b> (collapsed lung): difficulty breathing, rapid, shallow breathing, wheezing, cough		✓	
<b>Angina</b> : chest pain or discomfort		✓	
<b>Pleural Effusion</b> (fluid build up in the chest cavity): shortness of breath, chest pain especially when breathing in deeply, fever, cough		✓	
Wound secretion		✓	

<b>RARE</b>			
<b>Allergic Reaction:</b> difficulty swallowing or breathing, wheezing; drop in blood pressure; feeling sick to your stomach and throwing up; hives or rash; swelling of the face, lips, tongue or throat.		✓	
<b>Stroke</b> (bleeding or blood clot in the brain): sudden numbness, weakness or tingling of the face, arm, or leg, particularly on one side of the body, sudden headache, blurry vision, difficulty swallowing or speaking, or lethargy, dizziness, fainting, vomiting, trouble understanding, trouble with walking and loss of balance		✓	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

### **Reporting Side Effects**

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

### **Storage:**

As BIVALIRUDIN INJECTION is a hospital product only, storage of BIVALIRUDIN INJECTION is the responsibility of healthcare professionals.

BIVALIRUDIN INJECTION will be stored in the refrigerator (2–8°C) and not frozen.

### **If you want more information about BIVALIRUDIN INJECTION:**

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>); the manufacturer's website [www.avirpharma.com](http://www.avirpharma.com), or by calling 1-800-363-7988.

This leaflet was prepared by:

**AVIR Pharma Inc.**

660 Boul. Industriel

Blainville, Quebec

J7C 3V4

[www.avirpharma.com](http://www.avirpharma.com)

Last Revised September 24, 2020